As previously discussed on OPA, the U.S. Food and Drug Administration (FDA) organized a workshop this past April to examine access to naloxone as a means to reduce opioid overdose fatalities in the Unites States. FDA has now published the complete transcript of the event, available here (PDF).
We will post choice excerpts in coming weeks, but the entire transcript is worth reviewing and referencing, and includes testimony from leading advocates, researchers, and officials from CDC, FDA and SAMHSA among others.
One immediate way that advocates may follow up on the workshop is to submit comments on the subject, which FDA is accepting until June 12. Doing so will support efforts to convince FDA to take action on expanding naloxone access, which has included discussion of rescheduling the medication to remove prescription requirements. For information on how to submit comments and suggestions for doing so, follow this link.